The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Elite Pharmaceuticals's Revenue for the
three
months ended in Mar. 2026 was $40.7 Mil. Elite Pharmaceuticals's average Accounts Receivable for the
three
months ended in Mar. 2026 was $54.1 Mil.
Hence, Elite Pharmaceuticals's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.75.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Elite Pharmaceuticals Receivables Turnover Related Terms
Elite Pharmaceuticals Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Elite Pharmaceuticals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ELTP vs EBS, NIKA, EOLS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elite Pharmaceuticals Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Elite Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elite Pharmaceuticals (ELTP) has a Receivables Turnover of 0.75 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Elite Pharmaceuticals and its competitors. According to the industry distribution chart, Elite Pharmaceuticals ranks #709 out of 946 companies in the Drug Manufacturers industry, placing it in the top 74.9%.
Is Elite Pharmaceuticals' Receivables Turnover too high?
Elite Pharmaceuticals' current Receivables Turnover is 0.75. The Drug Manufacturers industry median Receivables Turnover is 5.07. Elite Pharmaceuticals' value of 0.75 is 85.2% below this industry median. Based on the distribution chart, Elite Pharmaceuticals ranks #709 out of 946 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Elite Pharmaceuticals has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' Receivables Turnover compare to EBS and NIKA?
According to the Drug Manufacturers industry distribution chart, Elite Pharmaceuticals ranks #709 out of 946 companies for Receivables Turnover. This places Elite Pharmaceuticals in the lower half of its industry. The industry median Receivables Turnover is 5.07. Elite Pharmaceuticals' value of 0.75 is 85.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elite Pharmaceuticals's current Receivables Turnover of 0.75 is 85.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Elite Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elite Pharmaceuticals's current Receivables Turnover is 0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.56, compared to a current price of $0.36 — trading 35.7% below its estimated fair value. The current Receivables Turnover is 0.75 and 85.2% below the Drug Manufacturers industry median of 5.07. Elite Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current Receivables Turnover is 0.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?
Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.36 is trading 35.7% below its estimated GF Value™ of $0.56.
GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.
Key valuation signals for ELTP:
Receivables Turnover: 0.75
GF Value™: $0.56 vs. price of $0.36 (35.7% below fair value)
Industry Position: 85.2% below the Drug Manufacturers median (#709 of 946)
No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
55GF Score
Get the complete analysis for ELTP
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTP has been successfully added to your 
